Medical Cost and Healthcare Resource Utilization Influenced by Anti-Platelet Agent Selection in Patients with Acute Coronary Syndrome

Download item | Update item information
Identifier 019_EAC2017_Medical_Cost_Healthcare_Resource_Utilization_KIM.pdf
Title Medical Cost and Healthcare Resource Utilization Influenced by Anti-Platelet Agent Selection in Patients with Acute Coronary Syndrome
Creator Kibum Kim, PhD; Daniel R. Touchette, Pharm D.; Todd A. Lee, Pharm; Amer K. Ardati, MD, MSf; Surrey M. Walton, PhDc; Robert J. DiDomenico, Pharm D, FCCPd
Subject Acute Coronary Syndrome; Anti-Platelet Agents; Medical Costs
Description Acute coronary syndrome (ACS), after receiving percutaneous coronary intervention (PCI), requires appropriate long-term antiplatelet therapy with a P2Y12 combination with aspirin.[1,2] Clopidogrel, a 2nd generation P2Y12 antagonist, has stood as the gold-standard, but two alternative options, prasugrel and ticagrelor, are now available in the US healthcare market. Multiple studies retrospectively analyzed and compared outcomes of different anti-platelet strategies in real-world ACS populations using administrative databases. However, due to methodological limitations, the studies potentially overestimated overall cost or did not account for the adherence on the initial treatment.
Relation is Part of 2017 Extreme Affordability Conference
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date Digital 2017
Date 2017
Format application/pdf
Rights Management Copyright 2017. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
Language eng
ARK ark:/87278/s6dn8hj6
Setname ehsl_eac
Date Created 2019-02-05
Date Modified 2019-03-04
ID 1399558
Reference URL https://collections.lib.utah.edu/ark:/87278/s6dn8hj6